连接和未满足的需求:严重喘生物学和骨质疏松症
Fabiana Furci1, Marco Umberto Scaramozzino2, Giuseppe Rocco Talesa3
1Provincial Healthcare Unit, Section of Allergology, 89900 Vibo Valentia, Italy.
Biomedicines
|January 25, 2025
概括
用于治疗喘的皮质类固醇增加了骨质疏松症和骨折的风险. 新的生物疗法和预防策略可以改善喘控制并减少这些与骨有关的风险.
科学领域:
- 肺部病理学 肺部病理学
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 喘是一种慢性炎症性呼吸道疾病.
- 皮质类固醇是喘管理的主要抗炎药物.
- 长期使用皮质类固醇与不良的骨健康结果有关.
研究的目的:
- 检查在喘中使用皮质类固醇与骨质疏松症和骨折风险之间的关联.
- 探索新生物疗法和预防策略在减轻这些风险方面的潜力.
主要方法:
- 审查关于喘药物治疗和骨健康的现有文献.
- 对将皮质类固醇暴露 (口服和吸入) 与骨密度和骨折发生率联系起来的数据的分析.
- 评估当前的指导方针和新兴的治疗模式.
主要成果:
- 单次口服皮质类固醇疗程和持续吸入皮质类固醇使用都会增加骨质疏松症的风险.
- 骨折风险增加是与喘患者的皮质类固醇治疗相关的显著并发症.
- 失控的喘会加剧与皮质类固醇相关的骨并发症的风险.
结论:
- 对喘的皮质类固醇治疗虽然对炎症有效,但对骨健康构成相当大的风险.
- 将生物疗法和积极的预防措施纳入喘管理计划至关重要.
- 优化喘控制和尽量减少皮质类固醇暴露可以帮助预防骨质疏松症等并发症.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
234
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
234
Drugs Used in Lower Respiratory Disorders: Overview
347
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
347
Antiasthma Drugs: Leukotriene Modifiers
239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
239
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


